Buparlisib Hydrochloride
$300.00
CAS No.: 1312445-63-8
Catalog No.: 193775
Purity: 95%
MF: C18H22ClF3N6O2
MW: 446.861
Storage: 2-8 degree Celsius
SMILES: Cl.O1CCN(CC1)C1=NC(=CC(=N1)C=1C(=CC(=NC1)N)C(F)(F)F)N1CCOCC1
Catalog No.: 193775
Purity: 95%
MF: C18H22ClF3N6O2
MW: 446.861
Storage: 2-8 degree Celsius
SMILES: Cl.O1CCN(CC1)C1=NC(=CC(=N1)C=1C(=CC(=NC1)N)C(F)(F)F)N1CCOCC1
Buparlisib Hydrochloride; 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine hydrochloride; CAS No.: 1312445-63-8;Buparlisib Hydrochloride. PROPERTIES: Buparlisib Hydrochloride appears as a white to off-white powder with a molecular formula of C23H26F3N5O3 HCl and a molecular weight of 524.97 g/mol. It has moderate solubility in water and better solubility in acidic conditions. Proper storage requires maintaining at 4 C in a sealed container protected from moisture. When handling, chemical-resistant gloves and eye protection are advised due to its pharmaceutical nature and potential for causing mild skin irritation. APPLICATIONS: Buparlisib is a pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. In oncology, it's used for treating advanced solid tumors, particularly breast and ovarian cancers, by blocking PI3K/AKT/mTOR signaling pathway (source: European Journal of Cancer). Clinical trials have demonstrated efficacy in combination with hormone therapies for PIK3CA-mutated breast cancers. Buparlisib Hydrochloride also serves as a research tool for studying PI3K pathway dysregulation in various disease contexts, including metabolic disorders and immunology (source: Nature Reviews Drug Discovery).
Reviews
Write Your Own Review